Strategic communications

Orphan drug firm Sobi opens new European base
Orphan drug firm Sobi opens new European base Company'sBrussels office will also house its Benelux operations
Orphan drug market to reach $176bn by 2020
Orphan drug market to reach $176bn by 2020 New report suggests market will almost double in five years
Channel strategy and orphan drugs
Channel strategy and orphan drugs A plan for guiding decisions about a product's distribution channel is particularly relevant for orphan drugs, rare diseases or specialty medicines
The distressing impact of rare diseases
The distressing impact of rare diseases Much more needs to be done to address the problem of effective communications with stakeholders and adequate information for patients affected
Orphan drugs: A 'responsible' investment
Orphan drugs: A 'responsible' investment There's growing sense of responsibility in the orphan drug market, but the market remains under-exploited by companies
The thing about small numbers
The thing about small numbers Marketers working in orphan drugs need to take a narrower, deeper approach to relationship building, and look to medical centres of excellence
Small diseases need big picture communications
Small diseases need big picture communications An early commitment to communications planning in rare diseases is worth the risk
Novartis sponsors rare disease patient community
Novartis sponsors rare disease patient community Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)
Rare disease patients face 5-7 year wait for diagnosis
Doctors often lack time and resources to manage patients
Novartis provides multimedia support to Rare Diseases Day
Novartis provides multimedia support to Rare Diseases Day Collaborates with Eurordis on multimedia education campaign
Result pages: 1 | 2 ()